Sponsored
As health technology assessments (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in development cycles.
Esther Nzenza, Senior Partner and Global Head of Value and Access
Advertisement
Articles by Esther Nzenza, Senior Partner and Global Head of Value and Access
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
3
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
5